We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Innovative Test Accurately Evaluates Liver Fibrosis Severity in Just 18 Minutes

By LabMedica International staff writers
Posted on 14 May 2025

Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 30% of the population and is one of the leading causes of chronic liver disease in developed countries. More...

Primarily caused by conditions like diabetes, obesity, and other cardiometabolic risk factors, MASLD is becoming increasingly prevalent, placing a significant burden on both patients and healthcare systems globally. Despite being responsible for about one in every 25 deaths worldwide, the liver fibrosis associated with MASLD often remains asymptomatic until it reaches advanced stages, and can go undetected for years. If left unmanaged, it can result in severe complications, including cirrhosis, liver cancer, and liver failure. Now, a new diagnostic test offers a way to identify patients with significant liver fibrosis at an earlier stage, which could lead to improved outcomes through timely treatment and access to emerging therapies.

Roche (Basel, Switzerland) has launched Elecsys PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of MASLD. The test, developed in partnership with Nordic Bioscience (Herlev, Denmark), provides clinicians with a simple, efficient method for identifying patients with varying levels of liver fibrosis, allowing for timely intervention and proper management of the disease. The Elecsys PRO-C3 test requires just one assay and delivers results in only 18 minutes on Roche's cobas analyzers, streamlining the diagnostic process and reducing costs compared to currently available tests. When combined with the ADAPT formula—which includes PRO-C3 levels, platelet count, age, and diabetes status—the test offers a comprehensive assessment of fibrosis severity, helping distinguish between stages like significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4).

This is particularly important for determining the appropriate treatment for patients and identifying those who could benefit from new and emerging therapies. Until recently, no medications were available for treating MASLD, and management focused mainly on lifestyle changes such as diet and exercise. However, new drug treatments for liver fibrosis are now emerging, offering clinicians the first opportunity to improve liver function and slow the progression of the disease. Initially, the ADAPT score will be calculated manually, but later this year, Roche plans to launch software that will automate this calculation, further simplifying the diagnosis of liver fibrosis.

"The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging and management of liver fibrosis," said Matt Sause, CEO of Roche Diagnostics. "With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies."


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.